SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Jordan J)
 

Search: WFRF:(Jordan J) > (2005-2009) > Angiotensin type 1 ...

  • Janke, JFranz Volhard Clinic (author)

Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome prolifertor-activated receptor-gamma activation

  • Article/chapterEnglish2006

Publisher, publication year, extent ...

  • Ovid Technologies (Wolters Kluwer Health),2006
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:liu-21107
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-21107URI
  • https://doi.org/10.1097/01.hjh.0000242405.68461.84DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • OBJECTIVE: In clonal animal cells, certain angiotensin receptor blockers (ARB) activate the peroxisome proliferator-activated receptor-gamma (PPARgamma). The aim of this work was to validate that observation in human cells and humans. METHODS: We investigated the induction of in-vitro adipogenesis and the activation of PPARgamma-target genes, adiponectin and lipoprotein lipase, by ARB in human preadipocytes. We also studied PPARgamma response-element-driven luciferase reporter gene activation in human adipocytes. Finally, we treated 14 obese men for 10 days with placebo crossed over with 150 mg/day irbesartan. Subcutaneous fat was analyzed for mRNA expression of adiponectin and lipoprotein lipase. RESULTS: Telmisartan and irbesartan, and to a lesser degree losartan, induced adipogenesis and activated PPARgamma-target genes. This stimulation of PPARgamma-target genes was prevented by the PPARgamma antagonist GW9662. Eprosartan had no effect. Paradoxically, all ARB activated the luciferase reporter gene. PPARgamma activity increased approximately two-fold with pioglitazone and 1.5-fold with the ARB in all assays. In the cross-over clinical study, irbesartan lowered blood pressure but had no effect on adiponectin or lipoprotein lipase mRNA expression. CONCLUSIONS: Our data are the first to show that ARB induce adipogenesis and PPARgamma-target gene expression in human adipocytes. Pharmacokinetic differences may contribute to the heterogeneous effects on metabolism and preadipocyte differentiation. In humans, larger doses of ARB, longer treatments, or both may be required to activate PPARgamma in adipose cells.

Subject headings and genre

  • MEDICINE
  • MEDICIN

Added entries (persons, corporate bodies, meetings, titles ...)

  • Schupp, Mn/a (author)
  • Engeli, Sn/a (author)
  • Gorzelniak, Kn/a (author)
  • Boschmann, Mn/a (author)
  • Sauma, LilianÖstergötlands Läns Landsting,Linköpings universitet,Internmedicin,Hälsouniversitetet,Endokrin- och magtarmmedicinska kliniken US(Swepub:liu)lilsa36 (author)
  • Nystrom, Fredrik HÖstergötlands Läns Landsting,Linköpings universitet,Internmedicin,Hälsouniversitetet,Endokrin- och magtarmmedicinska kliniken US(Swepub:liu)freny92 (author)
  • Jordan, Jn/a (author)
  • Luft, FCn/a (author)
  • Sharma, AMn/a (author)
  • Franz Volhard Clinicn/a (creator_code:org_t)

Related titles

  • In:Journal of Hypertension: Ovid Technologies (Wolters Kluwer Health)24:9, s. 1809-18160263-63521473-5598

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view